On September 8, 2022 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022 (Press release, Moleculin, SEP 8, 2022, View Source [SID1234619255]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentations are as follows:
Title: The Value of Collaboration in Clinical Development: Experience from Poland
Presenter: Walter Klemp, President and Chief Executive Officer
Session 2: Opportunities for International Collaborations & Funding
Date & Time: Friday, September 9 at 12:05 PM ET
Title: Translating Preclinical Research Into Clinical Trials
Presenter: Robert Shepard, MD, FACP, Medical Advisor
Session B: Translational Research
Date & Time: Saturday, September 10 at 11:10 AM ET